View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 12, 2019updated 12 Jul 2022 11:59am

Lilly launches trial to examine selpercatinib in NSCLC patients

Eli Lilly and Company has launched the LIBRETTO-431 Phase III clinical trial (NCT04194944) to examine selpercatinib (LOXO-292) for treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC) patients.

Eli Lilly and Company has launched the LIBRETTO-431 Phase III clinical trial (NCT04194944) to examine selpercatinib (LOXO-292) for treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A total of 400 patients with advanced or metastatic RET fusion-positive NSCLC will be enrolled for the randomised Phase III LIBRETTO-431 trial.

Participants in the trial will be randomised 1:1 to receive either selpercatinib or platinum-based carboplatin or cisplatin and pemetrexed therapy with or without pembrolizumab as an initial treatment for their advanced or metastatic RET fusion-positive NSCLC.

The primary endpoint of the study is progression-free survival (PFS) and secondary endpoints include overall survival (OS), overall response rate (ORR), duration of response (DoR), and intracranial ORR.

Crossover is allowed at progression for patients who are randomised to the control arm.

Lilly Oncology president Anne White said: “This is an important milestone in the journey to further demonstrate the benefit of selpercatinib and the potential for people living with advanced or metastatic RET fusion-positive non-small cell lung cancer in the first-line setting against the current standard of care.

“Launching a trial of this size underscores the importance of now including RET fusions in the paradigm of genomic testing in lung cancer.”

Selpercatinib, which has received breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers, is an oral investigational new medicine.

The drug is currently in clinical development to treat patients with cancers that harbour abnormalities in the rearranged during transfection (RET) kinase.

It can inhibit native RET signalling, as well as anticipated acquired resistance mechanisms.

In September this year, Lilly’s data from the LIBRETTO-001 clinical trial of selpercatinib showed positive response in NSCLC patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena